Does beta-lactam pharmacokinetic variability in critically III patients justify therapeutic drug monitoring? A systematic review

Annals of Intensive Care

Volumn 2, Issue 1, 2012, Pages

  Sime, Fekade Bruck ^a,b   Roberts, Michael S ^a,b,c   Peake, Sandra L ^b   Lipman, Jeffrey ^c,d   Roberts, Jason A ^a,c,d  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Antibiotics; Beta lactam; Critically ill; Pharmacodynamics; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFALOTIN; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; DICLOXACILLIN; ERTAPENEM; FLUCLOXACILLIN; MEROPENEM; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM;

ACUTE KIDNEY FAILURE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS HEMODIALYSIS; CONTINUOUS HEMOFILTRATION; CONTINUOUS INFUSION; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICALLY ILL PATIENT; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; HUMAN; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NEUROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEPSIS; SYSTEMATIC REVIEW (TOPIC); TOXICITY;

EID: 84866067012     PISSN: None     EISSN: 21105820     Source Type: Journal    
DOI: 10.1186/2110-5820-2-35     Document Type: Review

References (118)

1. Roberts JA, Norris R, Paterson DL, Martin JH: Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol 2012, 73:27-36.
2. van Lent-Evers NA, Mathot RA, Geus WP, van Hout BA, Vinks AA: Impact of goaloriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit 1999, 21:63-73.
3. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ: Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004, 43:925-942.
4. Ariano RE, Nyhlen A, Donnelly JP, Sitar DS, Harding GK, Zelenitsky SA: Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 2005, 39:32-38.
5. Li C, Du X, Kuti JL, Nicolau DP: Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007, 51:1725-1730.
6. Lodise TP Jr, Lomaestro B, Drusano GL: Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007, 44:357-363.
7. McKinnon PS, Paladino JA, Schentag JJ: Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Ag 2008, 31:345-351.
8. Niemiec PW Jr, Allo MD, Miller CF: Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care. Arch Surg 1987, 122:207-212.
9. Dorman T, Swoboda S, Zarfeshenfard F, Trentler B, Lipsett PA: Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading dose. Critical Care Research Group. Surgery 1998, 124:73-78.
10. Roos JF, Lipman J, Kirkpatrick CM: Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria. Intensive Care Med 2007, 33:781-788.
11. Joukhadar C, Frossard M, Mayer BX, Brunner M, Klein N, Siostrzonek P, Eichler HG, Muller M: Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001, 29:385-391.
12. Erlandsson M, Burman LG, Cars O, Gill H, Nilsson LE, Walther SM, Hanberger H: Prescription of antibiotic agents in Swedish intensive care units is empiric and precise. Scand J Infect Dis 2007, 39:63-69.
13. Roberts JA: Using PK/PD to optimize antibiotic dosing for critically ill patients. Curr Pharmaceut Biotechnol 2011, 12:2070-2079.
14. Mohr JF, Wanger A, Rex JH: Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients. Diagn Micr Infec Dis 2004, 48:125-130.
15. Goncalves-Pereira J, Povoa P: Antibiotics in critically ill patients a systematic review of the pharmacokinetics of beta-Lactams. Crit Care 2011, 15:R206.
16. Scaglione F: Can PK/PD be used in everyday clinical practice. Int J Antimicrob Ag 2002, 19:349-353.
17. Roberts JA, Hope WW, Lipman J: Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential? Int J Antimicrob Agents 2010, 35:419-420.
18. Lipman J, Wallis SC, Boots RJ: Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Analg 2003, 97:1149-1154.
19. Kieft H, Hoepelman AI, Knupp CA, van Dijk A, Branger JM, Struyvenberg A, Verhoef J: Pharmacokinetics of cefepime in patients with the sepsis syndrome. J Antimicrob Chemother 1993, 32(Suppl B):117-122.
20. Taccone FS, Laterre P-F, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent J-L, Jacobs F: Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010, 14:R126.
21. Gomez CM, Cordingly JJ, Palazzo MG: Altered pharmacokinetics of ceftazidime in critically ill patients. Antimicrob Agents Chemother 1999, 43:1798-1802.
22. Georges B, Conil J-M, Seguin T, Ruiz S, Minville V, Cougot P, Decun J-F, Gonzalez H, Houin G, Fourcade O, Saivin S: Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation, and reason for admission. Antimicrob Agents Chemother 2009, 53:4483-4489.
23. Douglas A, Udy AA, Wallis SC, Jarrett P, Stuart J, Lassig-Smith M, Deans R, Roberts MS, Taraporewalla K, Jenkins J, Medley G, Lipman J, Roberts JA: Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semi-elective abdominal aortic aneurysm open repair surgery. Antimicrob Agents Chemother 2011, 55:5238-5242.
24. Roberts JA, Kirkpatrick CMJ, Roberts MS, Dalley AJ, Lipman J: First-dose and steadystate population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Ag 2010, 35:156-163.
25. Garot D, Respaud R, Lanotte P, Simon N, Mercier E, Ehrmann S, Perrotin D, Dequin PF, Le Guellec C: Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal. Br J Clin Pharmacol 2011, 72:758-767.
26. Brink AJ, Richards GA, Schillack V, Kiem S, Schentag J: Pharmacokinetics of oncedaily dosing of ertapenem in critically ill patients with severe sepsis. Int J Antimicrob Ag 2009, 33:432-436.
27. Ulldemolins M, Roberts JA, Wallis SC, Rello J, Lipman J: Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. J Antimicrob Chemother 2010, 65:1771-1778.
28. Van Dalen R, Vree TB, Baars IM: Influence of protein binding and severity of illness on renal elimination of four cephalosporin drugs in intensive-care patients. Pharm Weekbl Sci 1987, 9:98-103.
29. Moon YS, Chung KC, Gill MA: Pharmacokinetics of meropenem in animals, healthy volunteers, and patients. Clin Infect Dis 1997, 24(Suppl 2):S249-S255.
30. Joynt GM, Lipman J, Gomersall CD, Young RJ, Wong EL, Gin T: The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother 2001, 47:421-429.
31. Udy AA, Putt MT, Shanmugathasan S, Roberts JA, Lipman J: Augmented renal clearance in the Intensive Care Unit: an illustrative case series. Int J Antimicrob Ag 2010, 35:606-608.
32. Burkhardt O, Kumar V, Katterwe D, Majcher-Peszynska J, Drewelow B, Derendorf H, Welte T: Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother 2007, 59:277-284.
33. Lipman J, Wallis SC, Rickard C: Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 1999, 43:2559-2561.
34. Delattre IK, Musuamba FT, Verbeeck RK, Dugernier T, Spapen H, Laterre P-F, Wittebole X, Cumps J, Taccone FS, Vincent J-L, Jacobs F, Wallemacq PE: Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin. Clin Biochem 2010, 43:589-598.
35. Benko AS, Cappelletty DM, Kruse JA, Rybak MJ: Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gramnegative infections. Antimicrob Agents Chemother 1996, 40:691-695.
36. Young RJ, Lipman J, Gin T, Gomersall CD, Joynt GM, Oh TE: Intermittent bolus dosing of ceftazidime in critically ill patients. J Antimicrob Chemother 1997, 40:269-273.
37. Thalhammer F, Traunmuller F, El Menyawi I, Frass M, Hollenstein UM, Locker GJ, Stoiser B, Staudinger T, Thalhammer-Scherrer R, Burgmann H: Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 1999, 43:523-527.
38. Novelli A, Adembri C, Livi P, Fallani S, Mazzei T, De Gaudio AR: Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet 2005, 44:539-549.
39. Burkhardt O, Derendorf H, Welte T: Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin Pharmacother 2007, 8:237-256.
40. Boselli E, Breilh D, Saux M-C, Gordien J-B, Allaouchiche B: Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia. Intens Care Med 2006, 32:2059-2062.
41. Burgess DS, Frei CR: Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics. J Antimicrob Chemother 2005, 56:893-898.
42. Tam VH, Louie A, Lomaestro BM, Drusano GL: Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy 2003, 23:291-295.
43. DeRyke CA, Kuti JL, Nicolau DP: Pharmacodynamic target attainment of six betalactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. Pharmacotherapy 2007, 27:333-342.
44. Zelenitsky SA, Ariano RE, Zhanel GG: Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data. J Antimicrob Chemother 2011, 66:343-349.
45. Aubert G, Carricajo A, Coudrot M, Guyomarc'h S, Auboyer C, Zeni F: Prospective determination of serum ceftazidime concentrations in intensive care units. Ther Drug Monit 2010, 32:517-519.
46. Hallam MJ, Allen JM, James SE, Donaldson PMW, Davies JG, Hanlon GW, Dheansa BS: Potential subtherapeutic linezolid and meropenem antibiotic concentrations in a patient with severe burns and sepsis. J Burn Care Res 2010, 31:207-209.
47. Burkhardt O, Kumar V, Schmidt S, Kielstein JT, Welte T, Derendorf H: Underdosing of ertapenem in critically ill patients with pneumonia confirmed by Monte Carlo simulations. Int J Antimicrob Agents 2010, 35:96-97.
48. Boyadjiev I, Boulamery A, Simon N, Martin C, Bruguerolle B, Leone M: Penetration of Ertapenem into Muscle Measured by In Vivo Microdialysis in Mechanically Ventilated Patients. Antimicrob Agents Ch 2011, 55:3573-3575.
49. Chapuis TM, Giannoni E, Majcherczyk PA, Chiolero R, Schaller M-D, Berger MM, Bolay S, Decosterd LA, Bugnon D, Moreillon P: Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care 2010, 14:R51.
50. Kiffer CRV, Kuti JL, Mendes CMF, Oplustil CP, Amarante JB, Biancalana ML, Xavier N, Nicolau DP: A pharmacodynamic strategy to optimize empirical antibiotic therapy for gram-negative bacteria in a Brazilian Intensive Care Unit. Braz J Infect Dis 2007, 11:183-185.
51. Craig WA: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-10. quiz 11-12.
52. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA: Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal Model. J Infect Dis 1988, 158:831-847.
53. Turnidge JD: The pharmacodynamics of beta-lactams. Clin Infect Dis 1998, 27:10-22.
54. Alou L, Aguilar L, Sevillano D, Gimenez M-J, Echeverria O, Gomez-Lus M-L, Prieto J: Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model. J Antimicrob Chemother 2005, 55:209-213.
55. Buijk SLCE, Gyssens IC, Mouton JW, Van Vliet A, Verbrugh HA, Bruining HA: Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Chemother 2002, 49:121-128.
56. Lipman J, Gomersall CD, Gin T, Joynt GM, Young RJ: Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J Antimicrob Chemother 1999, 43:309-311.
57. Nicolau DP, Lacy MK, McNabb JC, Quintiliani R, Nightingale CH: Pharmacokinetics of continuous and intermittent ceftazidime in intensive care unit patients with nosocomial pneumonia. Infect Dis Clin Prac 1999, 8:45-49.
58. Nicolau DP, McNabb J, Lacy MK, Quintiliani R, Nightingale CH: Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Ag 2001, 17:497-504.
59. Nicolau DP, McNabb JC, Lacy MK, Li J, Quintiliani R, Nightingale CH: Pharmacokinetics and pharmacodynamics of continuous and intermittent ceftazidime during the treatment of nosocomial pneumonia. Clin Drug Invest 1999, 18:133-139.
60. Roberts JA, Webb S, Paterson D, Ho KM, Lipman J: A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 2009, 37:2071-2078.
61. Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J: Piperacillin penetration into tissue of critically ill patients with sepsis-bolus versus continuous administration? Crit Care Med 2009, 37:926-933.
62. Roberts JA, Kirkpatrick CMJ, Roberts MS, Robertson TA, Dalley AJ, Lipman J: Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009, 64:142-150.
63. Abanades S, Nolla J, Rodriguez-Campello A, Pedro C, Valls A, Farre M: Reversible coma secondary to cefepime neurotoxicity. Ann Pharmacother 2004, 38:606-608.
64. Bresson J, Paugam-Burtz C, Josserand J, Bardin C, Mantz J, Pease S: Cefepime overdosage with neurotoxicity recovered by high-volume haemofiltration. J Antimicrob Chemother 2008, 62:849-850.
65. Dakdouki GK, Al-Awar GN: Cefepime-induced encephalopathy. Int J Infect Dis 2004, 8:59-61.
66. Malone RS, Fish DN, Abraham E, Teitelbaum I: Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2001, 45:3148-3155.
67. Isla A, Gascon AR, Maynar J, Arzuaga A, Toral D, Pedraz JL: Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients. Clin Ther 2005, 27:599-608.
68. Allaouchiche B, Breilh D, Jaumain H, Gaillard B, Renard S, Saux MC: Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 1997, 41:2424-2427.
69. Mariat C, Venet C, Jehl F, Mwewa S, Lazarevic V, Diconne E, Fonsale N, Carricajo A, Guyomarc'h S, Vermesch R, Aubert G, Bidault R, Bertrand J-C, Zeni F: Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation. Crit Care 2006, 10:R26.
70. Traunmuller F, Schenk P, Mittermeyer C, Thalhammer-Scherrer R, Ratheiser K, Thalhammer F: Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients. J Antimicrob Chemother 2002, 49:129-134.
71. Krueger WA, Neeser G, Schuster H, Schroeder TH, Hoffmann E, Heininger A, Dieterich H-J, Forst H, Unertl KE: Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous venovenous hemofiltration. Chemotherapy 2003, 49:280-286.
72. Tegeder I, Neumann F, Bremer F, Brune K, Lotsch J, Geisslinger G: Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. Clin Pharmacol Ther 1999, 65:50-57.
73. Bilgrami I, Roberts JA, Wallis SC, Thomas J, Davis J, Fowler S, Goldrick PB, Lipman J: Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration. Antimicrob Agents Chemother 2010, 54:2974-2978.
74. Keller E, Bohler J, Busse-Grawitz A, Reetze-Bonorden P, Krumme B, Schollmeyer P: Single dose kinetics of piperacillin during continuous arteriovenous hemodialysis in intensive care patients. Clin Nephrol 1995, 43(Suppl 1):S20-S23.
75. Arzuaga A, Maynar J, Gascon AR, Isla A, Corral E, Fonseca F, Sanchez-Izquierdo JA, Rello J, Canut A, Pedraz JL: Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration. J Clin Pharmacol 2005, 45:168-176.
76. Matzke GR, Frye RF, Joy MS, Palevsky PM: Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis. Pharmacotherapy 2000, 20:635-643.
77. Kroh UF, Lennartz H, Edwards DJ, Stoeckel K: Pharmacokinetics of ceftriaxone in patients undergoing continuous veno-venous hemofiltration. J Clin Pharmacol 1996, 36:1114-1119.
78. Bouman CSC, van Kan HJM, Koopmans RP, Korevaar JC, Schultz MJ, Vroom MB: Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing. Intens Care Med 2006, 32:2013-2019.
79. Meyer B, el GS A, Delle KG, Locker GJ, Heinz G, Jaeger W, Thalhammer F: How to calculate clearance of highly protein-bound drugs during continuous venovenous hemofiltration demonstrated with flucloxacillin. Kidney Blood Press Res 2003, 26:135-140.
80. Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J: Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 2009, 37:2268-2282.
81. Schetz M, Ferdinande P, Van den Berghe G, Verwaest C, Lauwers P: Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med 1995, 21:612-620.
82. Isla A, Gascon AR, Maynar J, Arzuaga A, Sanchez-Izquierdo JA, Pedraz JL: In vitro AN69 and polysulphone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapies. Chemotherapy 2007, 53:194-201.
83. Isla A, Maynar J, Sanchez-Izquierdo JA, Gascon AR, Arzuaga A, Corral E, Pedraz JL: Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients. J Clin Pharmacol 2005, 45:1294-1304.
84. Seyler L, Cotton F, Taccone FS, De Backer D, Macours P, Vincent JL, Jacobs F: Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care 2011, 15:R137.
85. Grill MF, Maganti RK: Neurotoxic effects associated with antibiotic use: management considerations. Brit J Clin Pharmaco 2011, 72:381-393.
86. Giles LJ, Jennings AC, Thomson AH, Creed G, Beale RJ, McLuckie A: Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit Care Med 2000, 28:632-637.
87. Robatel C, Decosterd LA, Biollaz J, Eckert P, Schaller MD, Buclin T: Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients. J Clin Pharmacol 2003, 43:1329-1340.
88. Ververs TF, van Dijk A, Vinks SA, Blankestijn PJ, Savelkoul JF, Meulenbelt J, Boereboom FT: Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration. Crit Care Med 2000, 28:3412-3416.
89. Thalhammer F, Schenk P, Burgmann H, El Menyawi I, Hollenstein UM, Rosenkranz AR, Sunder-Plassmann G, Breyer S, Ratheiser K: Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. Antimicrob Agents Chemother 1998, 42:2417-2420.
90. Valtonen M, Tiula E, Takkunen O, Backman JT, Neuvonen PJ: Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 2001, 48:881-885.
91. Mueller SC, Majcher-Peszynska J, Hickstein H, Francke A, Pertschy A, Schulz M, Mundkowski R, Drewelow B: Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis. Antimicrob Agents Chemother 2002, 46:1557-1560.
92. Dasgupta A: Handbook of Drug Monitoring Methods. In Introduction to Therapeutic Drug Monitoring. Edited by Therapeutic Drug Monitoring I, Dasgupta A. New Jersey: Humana Press Inc; 2008:1-39.
93. Dasgupta A: Advances in Chromatographic Techniques for Therapeutic Drug Monitoring. In Introduction to Therapeutic Drug Monitoring and Chromatography. Edited by Dasgupta A. Boca Raton: CRC Press Taylor and Francis Group, LLC; 2010:1-38.
94. Lam S, Gomolin IH: Cefepime neurotoxicity: case report, pharmacokinetic considerations, and literature review. Pharmacotherapy 2006, 26:1169-1174.
95. Ye R-H, Lin M-Y, Sung C-C, Lin S-H: Standard Dose of Piperacillin Induced Neurotoxicity in Advanced Renal Failure. Acta Nephrologica 2011, 25:89-92.
96. Huang W-T, Hsu Y-J, Chu P-L, Lin S-H: Neurotoxicity Associated with Standard Doses of Piperacillin in an Elderly Patient with Renal Failure. Infection 2009, 37:374-376.
97. Chow KM, Hui AC, Szeto CC: Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside. Eur J Clin Microbiol Infect Dis 2005, 24:649-653.
98. Conil J-M, Georges B, Mimoz O, Dieye E, Ruiz S, Cougot P, Samii K, Houin G, Saivin S: Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patients. Intens Care Med 2006, 32:2063-2066.
99. Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, Lipman J: Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Ag 2010, 36:332-339.
100. Blondiaux N, Wallet F, Favory R, Onimus T, Nseir S, Courcol RJ, Durocher A, Roussel-Delvallez M: Daily serum piperacillin monitoring is advisable in critically ill patients. Int J Antimicrob Agents 2010, 35:500-503.
101. Pea F, Cojutti P, Sbrojavacca R, Cadeo B, Cristini F, Bulfoni A, Furlanut M: TDMguided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient. Ann Pharmacother 2011, 45:e37.
102. Taccone FS, Cotton F, Roisin S, Vincent JL, Jacobs F: Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Ch 2012, 56:2129-2131.
103. Patel BM, Paratz J, See NC, Muller MJ, Rudd M, Paterson D, Briscoe SE, Ungerer J, McWhinney BC, Lipman J, Roberts JA: Therapeutic Drug Monitoring of Beta-Lactam Antibiotics in Burns Patients-A One-Year Prospective Study. Ther Drug Monit 2012, 34:160-164.
104. Connor MJ Jr, Salem C, Bauer SR, Hofmann CL, Groszek J, Butler R, Rehm SJ, Fissell WH: Therapeutic drug monitoring of piperacillin-tazobactam using spent dialysate effluent in patients receiving continuous venovenous hemodialysis. Antimicrob Agents Chemother 2011, 55:557-560.
105. Craig WA: Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995, 22:89-96.
106. Drusano GL: Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003, 36:S42-S50.
107. Mouton JW, den Hollander JG: Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994, 38:931-936.
108. Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA: Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005, 49:4920-4927.
109. Roberts JA, Lipman J: Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009, 37:840-851. quiz 859.
110. Verdier MC, Tribut O, Tattevin P, Le Tulzo Y, Michelet C, Bentue-Ferrer D: Simultaneous determination of 12 beta-lactam antibiotics in human plasma by highperformance liquid chromatography with UV detection: application to therapeutic drug monitoring. Antimicrob Agents Chemother 2011, 55:4873-4879.
111. McWhinney BC, Wallis SC, Hillister T, Roberts JA, Lipman J, Ungerer JP: Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878:2039-2043.
112. Morris RG, Tett SE, Ray JE: Cyclosporin A monitoring in Australia: consensus recommendations. Ther Drug Monit 1994, 16:570-576.
113. Ahrer W, Scherwenk E, Buchberger W: Determination of drug residues in water by the combination of liquid chromatography or capillary electrophoresis with electrospray mass spectrometry. J Chromatogr A 2001, 910:69-78.
114. Van Emon JM, LG C: Environmental monitoring and human exposure assessment using immunochemical techniques. J Microbiol Methods 1998, 32:121-131.
115. Norris RL, Martin JH, Thompson E, Ray JE, Fullinfaw RO, Joyce D, Barras M, Jones GR, Morris RG: Current status of therapeutic drug monitoring in Australia and New Zealand: a need for improved assay evaluation, best practice guidelines, and professional development. Ther Drug Monit 2010, 32:615-623.
116. Smith PF, Petros WP, Soucie MP, Copeland KR: New modified fluorescence polarization immunoassay does not falsely elevate vancomycin concentrations in patients with end-stage renal disease. Ther Drug Monit 1998, 20:231-235.
117. Benito-Pena E, Moreno-Bondi MC, Orellana G, Maquieira A, van Amerongen A: Development of a novel and automated fluorescent immunoassay for the analysis of beta-lactam antibiotics. J Agric Food Chem 2005, 53:6635-6642.
118. Usleber E, Litz S, Martlbauer E: Production and characterization of group-specific antibodies against penicillin antibiotics. Food Agric Immunol 1998, 10:317-324.